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ABSTRACT
At elevated levels, homocysteine (Hcy) is a risk factor for cardiovascular diseases and
Alzheimer’s disease. It’s also implicated in a number of other diseases such as neural tube
defects, pregnancy complications, and renal failures. The monitoring of Hcy levels in plasma is
of current concern. To date, the biochemical mechanism by which Hcy is involved in disease
states is unclear. Herein, we describe highly selective colorimetric methods for the direct
determination of Hcy. Inexpensive, commercially available materials are reported. The results
show potential application for the detection of Hcy in human blood plasma. Additionally, new
HPLC postcolumn detection methods for biological thiols are developed. The potential
biomedical relevance of the chemical mechanisms involved in the detection of Hcy is discussed.
In addition to the detection of bioactive amnino acids (such as Hcy and congeners), the
detection of neutral sugars has been of great interest and ongoing for over a century. A big
challenge remaining in this area is to achieve sensitive determination of specific saccharides at
physiologically relevant pH. Inspired by calcium-dependent recognition of saccharides by C-type
lectins, a water-soluble salophene-lanthanum complex was synthesized. It can be used in the
detection of neutral sugars at physiological pH.
Anionic sugar detection is also of importance to biomedical research. For instance, an
increase or decrease in total sialic acid levels in biological fluids or tissues can indicate the
occurrence of certain cancers. In the general procedure for the determination of sialic acid, a
hydrolysis step is typically required to release bound sialic acid residues from the
glycoconjugates. Two problems are often encountered in the hydrolysis: i) destruction of
analytes; ii) incomplete release of sialic acid residues. New effective sensing agents for the
determination of sialic acid are thus needed. A salophene-europium complex was synthesized

xiv

and used in the selective detection of sialic acid-containing gangliosides under neutral
conditions. Electrostatic interactions of Eu3+ with the carboxylate group of the sialic acid moiety
as well as the secondary interactions of Eu3+ with proximal oligosaccharide hydroxyls play
important roles in the signal transduction.

xv

CHAPTER 1. INTRODUCTION
The detection of bioactive sugars and amino acids is of great current interest. Our
program focuses on developing convenient methods for the selective detection of
biologically relevant molecules. My research involves new directions in the sensing of
amino acids, neutral sugars and anionic sugars.
1.1

Direct Detection of the Amino Acid Hcy Using Organic Sensing Agents
At elevated levels in blood plasma, the rare amino acid Hcy has been identified as

a risk factor for Alzheimer’s and cardiovascular diseases.1,2 It’s also implicated in a
number of other diseases such as neural tube defects, pregnancy complications and renal
failures.3-5 The detection of Hcy has thus attracted great interest in both the medical and
chemical fields. Many sensor technologies have been developed. However, most of the
work has relied on separation techniques due to interference from structurally similar
thiols. Immunoassays have been developed. However, immunoassay reagents are
relatively fragile and expensive in general as compared to synthetic organic reagents.
The actual role of Hcy in disease is unclear. After many years of study, it is still
not yet known if Hcy causes disease, is a consequence of disease or is simply a
biomarker.6 There is a significant need to uncover the role of Hcy in disease.
1.2

Syntheses of Lanthanide Complexes as Biosensors for Sugars
Metallomacrocycles have recently been employed in the field of supramolecular

chemistry.7,8

Most of these macrocycles are constructed with metal cation(s)

incorporated into organic ligands. Lanthanides can extend their ligand coordination
number via “ligand-sphere” extension, leading to highly coordinated complexes.9
Additionally, La3+ has been shown to exhibit relatively stronger affinity for sugars

1

compared to most other metal ions.10 Hence, we propose that the incorporation of La3+
into a salophene ligand may provide a useful receptor for the determination of
saccharides.
Additionally, effective new sensing agents are needed for the determination of
total sialic acid, which indicates the occurrence of certain cancers. A challenge is to
achieve the selective detection of sialic acids without using a hydrolysis step to release
bound sialic acid residues from gangliosides. Eu3+ has been reported to have higher
affinity to GM1 than to free sialic acid.11 Moreover, the smaller of the ionic radius of a
lanthanide, the larger are the intramolecular interactions among its ligands. Eu3+ has a
smaller ionic radius than that of La3+, we thus hypothesize that a Eu3+-salophene complex
may function as a good receptor for gangliosides.
1.3

Research Goals
My research goal is to detect biologically relevant amino acids and sugars under

physiological conditions, which mainly include (i) uncovering the differences in the
organic chemistry of biological thiols; (ii) understanding the fundamental organic
chemistry relevant to the involvement of Hcy in disease; (iii) creating simple new
methods which lead to selective, straightforward detection of Hcy; (iv) synthesizing new
sensing agents for neutral and anionic sugars.
The approach involves synthetic organic and organometallic sensing agents.
Understanding the mechanism of binding and signal transduction is an important aspect
of the work, particularly when it is relevant as a biomimetic process.
In the next chapter, the background on the aminothiol Hcy is presented.
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CHAPTER 2. BACKGROUND OF HCY
2.1

Discovery of Hcy
In 1932, Butz and du Vigneaud, at the University of Illinois, discovered a

compound by heating methionine in sulfuric acid.1 They found that this compound had
chemical properties similar to those of cysteine (Cys) and cystine. After characterization,
they named this compound “homocystine” since it’s the “next higher symmetrical
homolog of cystine”. They also concluded that homocystine was the oxidized form of
Hcy, which is formed during the hydrolysis of methionine.
Though Butz and du Vigneaud also pointed out that Hcy might support the
growth of animals on Cys-deficient diets, little was known about the broader biomedical
significance of this sulfur amino acid until the early 1960s, when children with mental
retardation, dislocation of ocular lenses, seizures and skeletal abnormalities were found to
have high concentrations of Hcy in the urine.2

The discovery of homocystinuria

(homocystine excreted in the urine) initiated an upsurge of research interest in Hcy.
2.2

Structures of Hcy and Other Biologically Related Thiols
As mentioned above, the structure of Hcy (1, Figure 2.1) is very close to that of

Cys (2, Figure 2.1). It has one more carbon in the side chain compared to Cys. As its
demethylation product, Hcy also resembles the essential amino acid methionine (3,
Figure 2.1). All three amino acids, Hcy, Cys and methionine, are metabolically linked.
Another structurally similar biological thiol is the tripeptide γ-glutamyl-cysteinyl-glycine,
glutathione (GSH, 4, Figure 2.1). Cys is the most abundant low-molecular-weight thiol in
plasma whereas GSH is the most predominant in cells. The biological function of GSH is
to remove harmful oxidizing agents and maintain the reducing environment inside cells.

4

GSH plays essential roles in antioxidant defense and regulation of cellular events such as
protein synthesis, gene expression, immune response and cell proliferation and apoptosis.
Other biologically relevant thiols include coenzyme A, dihydrolipoic acid and cysteamine.
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HO
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HO
NH2
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HO

NH2

homocysteine
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O
OH

NH2
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2

methionine
3

H
N

SH

O
O

NH

OH
glutathione
4

Figure 2.1. Structures of some biological thiols
2.3

Hcy Metabolism
Hcy is an intermediate metabolite in the metabolism of methionine (Scheme 2.1).

In biological systems, S-adenosylmethionine (SAM) serves as the most widely used
methyl donor for many reactions. Therefore, it’s often called the universal methylating
agent. SAM is synthesized from a reaction of L-methionine with ATP, catalyzed by
enzyme methionine adenosyltransferase.3 In the presence of a methyl-transferase, SAM
is then demethylated to give rise to S-adenosylhomocysteine (SAH).4 SAH is
subsequently broken down to Hcy and adenosine by the enzyme S-adenosylhomocysteine
hydrolyase.5 Nicotinamide adenine dinucleotide (NAD+) is required as a cofactor in this
reaction.
The Hcy formed can enter two distinct metabolic pathways. First, it can be
remethylated back to methionine and thus conserved within the methionine cycle. During
the remethylation, Hcy receives a methyl group either from methyltetrahydrofolate or
from betaine (trimethylglycine) to form methionine.6 Secondly, Hcy can be converted to
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Cys via an irreversible transsulfuration pathway, in which Hcy reacts with serine in the
presence of cystathionine-β-synthase (a vitamin B6-dependent enzyme) to afford
cystathionine.7
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Scheme 2.1. Metabolism of Hcy
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O

Glutathione

The cystathionine formed is then hydrolyzed to generate Cys with another
enzyme, cystathionine γ-lyase.7,8

The irreversibility of this pathway indicates the

inability of Cys to serve as a precursor for methionine. Once Cys is generated, about 70%
is rapidly converted to the tripeptide GSH.9 The distribution of Hcy among these two
competing pathways depends on two factors ― the tissue content of the relevant enzymes
and the kinetic properties of the enzymes.6, 10
Beside the above mentioned two metabolic pathways, Hcy can also form an
intramolecular thioester, homocysteine thiolactone. Homocysteine thiolactone is
chemically reactive and can easily acylate the free amino groups of proteins.11
2.4

Homeostasis of Hcy
The intake of Hcy from the diet is very small. The majority of Hcy is produced by

the metabolism of methionine. Many factors affect the distribution of Hcy in the body
resulting in a variety in physiological levels. Hcy metabolism depends on related
enzymes and their proper function, adequate levels of substrates and associated amino
acids, as well as efficient vitamin levels. Small metabolic changes will affect the
distribution of Hcy among different tissues, cells, intracellular compartments and
extracellular media. Moreover, intracellular import and export, cellular uptake and output
as well as transport also influence the distribution of Hcy. Mechanistic understanding of
the distribution and the transportation of Hcy in human body is of importance for
understanding of its possible roles in disease.
2.5

Hcy in Plasma
Hcy is found in several forms after being released into plasma.12-14 Most Hcy

(more than 70%) is conjugated to proteins. About 5-15% is present as homocystine.

7

Another 5-15% forms mixed disulfides with other low-molecular-weight thiols such as
Cys and GSH. Hcy exists only in small amount as free, reduced form (<1%). Thus the
term, total Hcy, is used to refer to the sum of the concentrations of all free plus disulfide
bound Hcy.14
The oxidation of Hcy to disulfides in plasma is coupled to the reduction of O2
giving rise to the formation of hydrogen peroxide (H2O2), which is thought to lead to
oxidative stress.8 However, more recent evidence indicates that most of the oxidized Hcy
(disulfides) arise primarily from disulfide exchange reactions. Only a small fraction of
disulfides result from direct oxidation reactions.15
Hcy can also react with nitric oxide (NO), which is released by endothelial cells
to form S-nitrosohomocysteine (SNOHO). SNOHO is a strong antiplatelet and
vasodilator agent. The nitrosylation of Hcy, on one hand, lowers the availability of NO,
which is a neurotransmitter and involved in muscle relaxation.16 On the other hand, the
nitrosylation reduces the production of peroxide and therefore inhibits the formation of
reactive oxygen species (ROS).17
The reduced form of Hcy can also undergo a reversible reaction to form
homocysteine thiolactone (Scheme 2.1). However, the concentration of homocysteine
thiolactone in plasma is very low (nanomolar) due to non-specific enzymatic hydrolysis.
Homocysteine thiolactone can also form an amide bond readily with the epsilon nitrogen
of lysine residues (vide infra).18
2.6

Relevance of Hcy to Public Health
When the metabolic pathway of Hcy to either methionine or Cys is disrupted due

to genetic defects or nutritional deficiency, the export of Hcy from the cellular medium to
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the extracellular medium will be imbalanced, resulting in the elevation of Hcy levels in
blood plasma (hyperhomocysteinemia) or urine (homocystinuria). At elevated levels in
plasma, Hcy has been confirmed as an independent risk factor for Alzheimer’s and
cardiovascular diseases.19,20 It’s also implicated in a number of other diseases such as
neural tube defects,21 pregnancy complications,22 and renal failures.23
•

Alzheimer’s Disease
Alzheimer’s disease is a disorder in the human brain. The disease was named after

a German doctor, Alois Alzheimer. In 1906, Dr. Alzheimer first described the disease. He
found abnormal clumps and tangled fibers in the brain tissue of a woman who had died of
a mental illness. Today, these clumps and tangles, which are believed to disrupt the
transmission of impulses amongst brain cells, are considered the signs of the disease.
The causes of Alzheimer’s disease are still unclear. But research has shown that
patients with Alzheimer’s disease have significantly higher circulating levels of Hcy than
healthy control subjects.24 Oxidative stress may cause Alzheimer’s disease. For instance,
the over expression of glutathione peroxidase was found in Alzheimer patients, linking
the disease to oxidative stress in the brain. Further evidence for the role of oxidative
stress is that antioxidant supplements can delay the Alzheimer's-related disorders.
Recent research results by Lipton et al. indicate that Hcy is a neurotoxin.25 Hcy
can interact with the N-methyl-D-aspartate (NMDA) receptor and consequently cause
excessive calcium influx and free radical production, resulting in neurotoxicity.
•

Cardiovascular Diseases
Cardiovascular diseases include the dysfunctional conditions of heart and blood

vessels, which supply oxygen and nutrition to the body. Hcy elevation has been identified
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as an independent risk factor for vascular disease in the coronary, cerebral and peripheral
circulation.26 The first human study of Hcy in vascular disease was carried out in 1976. It
showed that oral loading of methionine caused the increase of levels of homocystine and
Hcy-Cys mixed disulfide in the plasma of patients with coronary heart disease.27 It has
been reported that 20%-30% of patients with coronary disease have moderately elevated
Hcy levels either in the fasting state or after a methionine load.28 In spite of a clear
association of elevated Hcy with vascular disease, whether the excess Hcy itself confers
vascular risk or it’s just a secondary phenomenon still needs to be addressed.
Additionally, increased levels of Hcy are strongly correlated to standard risk factors of
vascular diseases such as smoking, gender, elevated lipids and aging. When determining
the independent contribution of Hcy, these factors need to be considered.
•

Renal Disease
Kidneys metabolize Hcy and are responsible for the clearance of plasma Hcy

under physiological conditions. When the metabolism of Hcy in kidneys is interrupted,
Hcy clearance will be reduced. Consequently, the concentration of Hcy in plasma will
increase. It has been found that Hcy levels were significantly increased in patients with
chronic renal failure and transplant recipients with impaired renal function.29,30
•

Neural Tube Defects and Other Pregnancy Complications
Experimental results from animal models indicate that elevated Hcy might be a

teratogenic agent contributing to congenital defects of neural tubes.31 Hcy metabolism is
involved in several biochemical pathways of the production of some nutrients, which are
essential to the vascular, skeletal and nervous systems. Therefore, the disturbance of Hcy
metabolism might be the underlying mechanism of the pathogenesis of neural tube
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defects.32 Other pregnancy complications, such as spontaneous abortion, placental
abruption, preterm delivery and low infant birth weight have also been associated with
elevated Hcy levels.22
2.7

Nutritional Intervention
Nutritional

supplementation

offers

a

way

to

prevent

and

treat

hyperhomocysteinemia. In 1988, Kang et al. reported an inverse relationship between
plasma Hcy and folate concentration.33 Further studies confirmed that folate, vitamins
and other nutrients can lower the concentration of Hcy in plasma.34-38 Selhub et al.
studied the independent correlations between individual nutrients and plasma Hcy
levels.39 After controlling gender, age and other nutrients, they found that nonfasting
plasma Hcy showed inverse relationships with folate, vitamin B12, B6, and pyridoxal-5’phosphate.

Among

the

studied

population,

two

thirds

of

participants with

hyperhomocysteinemia are attributed to vitamin deficiency.
2.8

Hcy’s Role in Disease
After many years of intensive study and impressive progress, it is still not yet

known if Hcy causes disease, is a consequence of it, or is simply a biomarker. There is an
ongoing

effort

in

the

biomedical

community

involving

the

study

of

hyperhomocysteinemia and the role of Hcy in disease.
The role of Hcy in disease is controversial. Hcy has been reported to inhibit the
oxidation of luminol and the dihydrorhodamine by strong oxidants.40 Hcy also rapidly
reduced ferrylmyoglobin to metmyoglobin.40 In a comparative study of the ability of
GSH, Cys and Hcy to reduce dehydroascorbic acid (DHA), Hcy promoted much more
significant reduction of DHA than Cys and GSH. Furthermore, the reduction occurred at
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Hcy concentrations that were over an order of magnitude smaller than those of GSH and
Cys.41 Thus, Hcy may function as a relatively potent reducing agent and plays a
protective role in diseases.
On the other hand, Hcy is considered as a causative factor. Initially, it was
believed that Hcy promoted the generation of ROS due to auto-oxidation reactions.42 But
recently, this hypothesis has been challenged. In human plasma, Cys is present in much
higher concentrations (exceeding those of Hcy by 20-30 folds). Cys can undergo similar
oxidative chemistry to that of Hcy. However, Cys has not typically been associated with
oxidative stress. Additionally, another biologically relevant thiol, GSH, is typically
associated with beneficial antioxidant activity. GSH scavenges free radicals and ROS (e.g.
H2O2) via non-enzymatic or enzymatic reactions.43,44 It is believed that GSH deficiency,
instead of elevation, plays a role in oxidative stress and contributes to aging and many
diseases.
Some scientists believe that Hcy has a direct effect on vascular cells and tissues
and causes cellular degeneration, damage to arterial intima, deposition of lipoproteins and
so on.27 Elevated levels of Hcy result in increased vascular accumulation of ROS,
especially superoxide anion.45-47 Superoxide anion reacts rapidly with endotheliumderived NO to form peroxynitrite. This reduces the bioavailability of NO, an
antiatherogenic molecule and contributes to decreased vasodilator capacity. In addition,
peroxynitrite is highly reactive towards protein oxidation. However, the precise
mechanism by which Hcy may induce the formation of ROS and peroxynitrite remains to
be elusive.
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Therefore, mechanistic understanding of the role of Hcy in disease is of great
importance for developing effective biomedical strategies to improve health and to treat
disease. The following chapter describes known methods for Hcy detection.
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CHAPTER 3. OVERVIEW OF ANALYTICAL METHODS FOR THE
DETECTION OF HCY
Due to the important biological relevance of Hcy, the detection of Hcy in
biological fluids has attracted high interest in both the medical and chemical fields. A
large number of prospective methods for the detection of Hcy have been published in the
literature. Most methods available can be divided into two categories: direct methods and
indirect methods. Direct methods mainly refer to immunoassays such as enzyme
immunoassay (EIA), fluorescence polarization immunoassay (FPIA) and enzyme-linked
immunosorbent assay (ELISA). Most indirect methods are based on separation
techniques

including

liquid

chromatography

(LC),

high

performance

liquid

chromatography (HPLC), capillary electrophoresis (CE) and gas chromatography (GC).
3.1

Sample Pretreatment
All methods for the detection of Hcy include a reduction step to release free Hcy

from its –S-S- bound forms before the detection. Lots of reducing agents have been used.
Usually, these agents are sulfhydryl (-SH) containing compounds or phosphines, such as
dithiothreitol (DTT), mercaptoethanol, tri-n-butylphosphine and tris (2-carboxyethyl)
phosphine (TCEP).1-3
3.2

Immunoassays
Immunoassays combine the theories of chemistry and immunology to facilitate a

specific and sensitive determination of a certain analyte. The crux of an immunoassay is
the specificity of the antibody-antigen reaction. Several immunoassays have been
developed.
In 1985, Refsum et al. reported a radioenzymic assay for the determination of
Hcy in plasma and urine.4 Reduction of disulfides with the reducing agent DTT released
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the free Hcy, which was consequently converted to S-[14C] adenosylhomocysteine.
Quantification of S-[14C] adenosylhomocysteine by HPLC and liquid scintillation
counting eventually gave the concentration of Hcy.
To avoid the use of radioisotopes, EIA and FPIA were introduced for the
determination of Hcy.5,6 The general principle of these two assays is based on enzymatic
conversion of free reduced Hcy to S-adenosylhomocysteine (SAH), followed by
quantification of SAH with the use of a monoclonal anti-SAH antibody.
The most attractive feature of an immunoassay is its selectivity. However,
radioimmunoassays often involve toxic substances. EIA and FPIA have high capacity but
also show some imprecision.7
3.3

Liquid Chromatography – Mass Spectrometry (LC-MS)
The small sample demand and rapid processing time make the LC-MS an

advantageous method with large capacity. In addition, its high accuracy also makes it a
potential candidate for reference methods.8,9

However, it requires cumbersome and

expensive equipment, which is not suitable for clinically diagnostic applications.
3.4

HPLC
HPLC has been largely used in the determination of Hcy as it can be readily

coupled with various detection methodologies. Synchronous detection of different thiols
in a same run is another advantage of the method. Furthermore, this technology can be
easily automated.
•

HPLC with Fluorometric Detection
Fluorescence spectroscopy is a widely used method due to its high sensitivity and

reliability.

Because Hcy itself is non-fluorescent, the determination of Hcy with
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fluorescence relies heavily on a derivatization step, in which Hcy reacts with
fluorophores to generate detectable species.
Several molecules have been utilized for the derivatization of Hcy. For instance,
Araki and Sato have used ammonium 7-fluoro-2,1,3–benzoxadiazole-4-sulphonate (SBDF, Figure 3.1) as a pre-column derivatizing agent.10 o-Phthalaldehyde (OPA, Figure 3.1)
is a fast derivatizing agent for a wide range of amino thiols over an extensive pH range.11
Monobromobimane (mBrB, Figure 3.1)12-14 and other derivatizing agents have also been
utilized by several research groups. However, most of these reagents are unselective and
have some drawbacks and limitations (Table 3.1).
Table 3.1. Several commonly used fluorophores and their limitations
Derivatizing agent

Limitations

monobromobimane
labeling

(i) Unstable at room temperature and in H2O; (ii) batch to
batch varying impurity levels; (iii) fluorescent hydrolysis
products produced upon labeling (iv) gradient and
relatively complex elution chromatography needed.

iodoacetamide
labeling

(i) Cross-reactivity with His, Tyr and Met; (ii) promotes
loss of NH3 upon reaction with Cys residues; (iii)
weakens mass spectrometric sensitivity.

o-phthalaldehyde
labeling

(i) Highly pH sensitive reaction; (ii) thiol adduct exhibits
high photo-instability; (iii) cross reactivity with many
other amino acids

maleimide labeling

(i) Hydrolysis peaks are encountered at the beginning and
end of chromatographic elution; (ii) cross linking to
amines; (iii) unwanted rearrangements of conjugates

hexaiodoplatinate
labeling

Broad cross-reactivity with interferences including
thioethers, thiazolidines and ascorbic acid
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Figure 3.1. Examples of fluorescent derivatizing agents
•

HPLC with UV/Vis Detection
UV/Vis detectors have also been used in the detection of Hcy. In order to develop

a useful and efficient technique, a derivatization step is needed. The derivatizing agents
must be able to react rapidly with Hcy to form stable products with sufficient UV/Vis
absorption. 2-Chloro-1-methylpyridinium iodide (CMPI, Figure 3.2) is a commonly used
derivatizing agent.15-16 2-chloro-1-methylquinolinium tetrafluoroborate (CQMT, Figure
3.2), a derivative of CMPI, has also been used.17

Me
N

Me
N

Cl
I

CMPI

Cl
BF4
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Fgure 3.2. Examples of UV/Vis derivatizing agents
•

HPLC with Electrochemical Detection
The redox chemistry of –SH group in Hcy makes it suited for electrochemical

detection. Hcy can be chemically oxidized to homocystine at bare electrodes is the
sensing root in this detection methodology. As the measurement can be directly carried
out at the electrode surface, no derivatization is needed prior to the chromatographic
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separation. A number of electrode substrates, including carbon,18,19 glassy carbon,20,21
graphite,22 platinum,23

gold,24-27 and silver28 have been exploited. To improve poor

voltammetric responses with these common substrates, the use of bismuth-doped lead
dioxide29 and boron doped diamond electrodes30 have been employed. Solid electrodes
coupled with electron transfer mediators also have been utilized.31-41

In order to

overcome the leaching of mediators from the surface of electrodes, carbon paste
electrodes, into which the mediator can be mixed, have been used.42 Though the shorter
run time is a major advantage of electrochemical detection over the aforementioned two
methods, it still suffers from problems such as low reproducibility and high imprecision,
which are due to the deterioration of measurement cells.1
3.5

CE
As a commonly used separation technique, CE has been utilized in the detection

of Hcy. Similar to HPLC, CE is often combined with different detection strategies, for
instance, electrochemical detection, fluorescence detection and UV/Vis spectroscopy. CE
coupled with different detection methods has been a complementary technique to HPLC.
•

CE with Electrochemical Detection
Normally, direct detection of Hcy on common solid electrodes is very difficult

due to the slow electron-transfer kinetics. In addition, electrode alignment and isolation
of the detector from the separation voltage makes the CE-electrochemical detection more
complicated. There are several sensitive and selective techniques that have been
presented with modified electrodes. O’Shea et al. have developed a thiol-specific method
with a gold/mercury-amalgamated electrode.43 Pasas et al. described a microchip using a
CE-electrochemical detection format for the determination of Hcy.44 Amongst the
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modified electrodes, the one chemically modified with pyrroloquinoline quinone shows
potential.45
•

CE with Fluorescence Detection
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CH2Br
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Figure 3.3. Commonly used fluorophores for CE
Just as in HPLC-fluorescence detection, CE with fluorescence detection also
requires a derivatization step. Several fluorogenic agents including fluorescein
isothiocyanate (FITC),46 bromomethylfluorescein (BMF),47 6-iodoacetamidofluorescein
(IAAF),48 4-aminosulfonyl-7-fluoro-2,1,3-benzoxadiazole (ASFB),49,51 and fluorescein5-maleimide (FMI),50 have been used for the derivatization (Figure 3.3).
•

CE with UV/Vis Detection
Compared to electrochemical and fluorescence detection, UV/Vis detection is

rarely used due to its lack of sensitivity.
3.6

GC
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GC is seldom used in the detection of Hcy because of the incompatibility of thiols
with the GC system.52 Only a few assays have been reported to date. Outlined below is a
summary of currently available methods using GC for the detection of Hcy.
•

GC with Mass Spectrometry (GC-MS)
Derivatization of Hcy with ethyl chloroformate to generate a volatile amino acid

ester has been described by Pietzsch et al..53

Another derivatizing agent N-(tert-

butyldimethylsilyl)-N-methyltrifluoroacetamide has also been introduced.54,55 Although
the derivatization processes are time-consuming, the assay developed is very reliable and
sensitive and has been considered as a reference method.
•

GC with Flame Photometric Detection (GC-FPD)
A selective method for the detection of total blood plasma Hcy has been reported

by a research group at Okayama University in Japan.56 After reduction, the free reduced
Hcy was converted to its N,S-diisopropoxycarbonyl methyl ester derivative, which was
then detected by flame photometric detection.
•

GC with Electron Capture Detector (GC-ECD)
Myung et al. have developed a selective and sensitive method for the detection of

Hcy and related biological thiols by GC-ECD.57 The analytes were first reduced to their
free thiol forms, which were consequently converted to their N (O, S)-ethylcarbonyl
pentafluoropropyl esters. After extracted with chloroform and hexane, the derivatized
analytes were determined by GC-ECD.
3.7

Conclusion
Due to interferences from the biological matrix, the determination of Hcy in

biological fluids is often carried out in conjunction with separation techniques such as LC,
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GC, HPLC and CE. Several detection protocols including electrochemical detection,
UV/Vis and fluorescence spectroscopy have been reported. All of these techniques have
shown different advantages and limitations.
The highly useful commercial immunoassays monitor one analyte at a time and
utilize relatively fragile biological materials. In addition, immunoassay reagents are
relatively expensive compared to common chemical reagents.
Furthermore, as stated by Refsum et al. in their comprehensive 2004 review coauthored by a group of the world’s leading experts in this field,58 many analytical
methods afford results that do not fulfill baseline bias and imprecision criteria.
Interlaboratory, inter and intrapatient errors in the determination of Hcy and other
biological thiols persist. There is a need for reference methods and/or standardized
methods, which should provide high selectivity, sensitivity together with high efficiency
and precision.
In following two chapters, a new colorimetric method and a new automatic
postcoulmn HPLC method developed in our lab for the detection of Hcy will be
described.
3.8
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CHAPTER 4. COLORIMETRIC DETECTION OF HCY*
Methods for the direct detection of Hcy are hampered due to interference from
common, structurally related biological thiols such as Cys and GSH. Hcy analyses are
thus often performed in conjunction with separation techniques. As part of our program
for the selective detection of colorless biomolecules,1

we develop highly selective

methods for the determination of Hcy by using inexpensive, commercially available
materials, such as methyl viologen (MV2+) and 9-phenyl 2,3,7-trihydroxy-6-fluorone
(fluorone black, FB). The chemical mechanism involved in the detection promotes the
understanding of the unique organic and bioorganic chemistry of Hcy and may also help
understand the role of Hcy in disease.
4.1

Experimental Section

•

General
All chemicals were purchased from Sigma-Aldrich or Cambridge Isotope Labs

and used without further purification. UV/Vis data were obtained using a Spectramax
Plus 384 spectrophotometer (Molecular Devices). Fluorescence spectra were recorded
using a spectrofluorimeter SPEX Fluorolog-3 equipped with double excitation and
emission monochromators and a 400 W Xe lamp. All spectroscopic data were recorded at

* Reprinted in part with permission from Journal of the American Chemical Society, 2004,
Volume 126, pages 3400-3401; Weihua Wang, Jorge O. Escobedo, Candace M.
Lawrence, and Robert M. Strongin; Direct Detection of Homocysteine. Copyright 2004
American Chemical Society.
* Reprinted in part with permission from Journal of the American Chemical Society, 2005,
Volume 127, pages 15949-15958; Weihua Wang, Oleksandr Rusin, Xiangyang Xu, Kyu
Kwang Kim, Jorge O. Escobedo, Sayo O. Fakayode, Kristin A. Fletcher, Mark Lowry,
Corin M. Schowalter, Candace M. Lawrence, Frank R. Fronczek, Isiah M. Warner, and
Robert M. Strongin; Detection of Homocysteine and Cysteine. Copyright 2005 American
Chemical Society.

32

room temperature. Matrix Assisted Laser Desorption Ionization Mass spectra were
acquired using a Bruker Proflex III MALDI mass spectrometer with and without matrix
(anthracene or dithranol). NMR spectra were obtained in 70% CD3OD, 30% D2O on a
Bruker DPX-250 or DPX-300 spectrometer, unless otherwise indicated.
•

Detection of Hcy with MV2+
Equimolar amounts of Hcy, Cys and GSH are dissolved in three 1mL solutions of

MV2+ (4.0 mM) in tris buffer (0.1M, pH 7.5), respectively, to furnish solutions with final
concentration of thiol at 17 mM. 1mL of the same MV2+ solution containing no thiol is a
control. All samples are gently refluxed on a hot plate until a blue color forms in the Hcycontaining solution (5 min).
•

Detection of Hcy in Human Blood Plasma with MV2+
Commercial lyophilized human blood plasma is reconstituted with distilled H2O.

Three 0.5 mL aliquots of reconstituted plasma are spiked with Hcy, Cys and GSH,
respectively. The concentration of added thiols in plasma is 800 μM. 0.5 mL of the same
reconstituted plasma containing no thiol is used as a control. Each of the above plasma
samples is mixed with 0.5 mL of the solution of MV2+ (800 μM) in tris buffer (0.5 M, pH
7.5). All samples are refluxed on a hot plate until a blue color forms in the Hcycontaining plasma sample.
•

Detection of Hcy with FB
Hcy, Cys or GSH is dissolved in a 0.005 M, pH 7.3 phosphate buffer, respectively,

to make a solution with the final concentration at 1.0 ×10-3 M. FB is dissolved in
methanol to make a solution of 1.44 ×10-5 M. 0.1mL of each thiol solution is mixed with
0.2mL of 0.005 M, pH 7.3 phosphate buffer and 0.7mL of FB solution. 0.3mL of 0.005
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M, pH 7.3 phosphate buffer mixed with 0.7mL of FB solution is taken as the control. All
samples are stirred for 5 min at room temperature before UV/Vis spectra are acquired.
•

Detection of Hcy with FB in the Presence of Triphenylphosphine (PPh3)
Hcy, Cys or GSH is dissolved in a 0.005 M, pH 7.3 phosphate buffer,respectively,

to afford a solution with a final concentration at 1.0 ×10-3 M. FB is dissolved in methanol
to make a solution of 2.5 ×10-5 M. PPh3 is dissolved in methanol to make a solution with
the concentration of 1.5 ×10-3 M. 0.1mL of each thiol solution is mixed with 0.2mL of
0.005 M, pH 7.3 phosphate buffer, 0.3mL of PPh3 solution and 0.4mL of FB solution.
0.3mL of 0.005 M, pH 7.3 phosphate buffer mixed with 0.3mL of PPh3 solution and
0.4mL of FB solution is used as a control. All samples are stirred for 5 min at room
temperature before UV/Vis spectra are acquired.
•

Detection of Hcy in Human Blood Plasma with FB
Commercial lyophilized human blood plasma is reconstituted with distilled H2O.

Disulfide-bound thiols are liberated from proteins by stirring the reconstituted plasma in a
commercial disulfide reducing agent, TCEP gel. This is followed by deproteinization
upon addition of MeOH which also contains PPh3 (1.5 x 10-3 M). After centrifugation
(5.0 min, 3000 g), the supernatant is filtered through a 0.45 mm filter.
For percent (%) recovery determinations, known amounts of Hcy are added to
reconstituted plasma samples before reduction and deproteinization steps. After the
reduction and deproteinization, the spiked plasma samples are mixed with FB solutions.
UV/Vis spectra are then obtained.

The absorbance difference with respect to the

unspiked sample is correlated with the concentration of added Hcy. The calibration curve
is thus constructed. The Hcy concentration present in the commercial blood plasma
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sample is determined from the calibration curve by subtracting the absorbance of a nonreduced plasma solution containing FB and PPh3 from the absorbance of a reduced
plasma sample containing FB and PPh3.
•

Effect of EDTA on the Detection of Hcy with FB
A 0.2 mL aliquot of a solution of EDTA (1.0 × 10-3 M) in 0.05 M, pH 7.3

phosphate buffer is added to 0.1 mL of a solution of Hcy (1.0 × 10-3 M) in the same
phosphate buffer. A mixture of 0.2mL of the same phosphate buffer and 0.1mL of Hcy
solution is taken as the control. The mixtures are stirred for 5 min at room temperature.
The UV/Vis spectra are acquired after the addition of 0.7 mL of FB solution (1.44 × 10-5
M) in MeOH to the above samples.
•

Effect of Fe3+ on the Detection of Hcy with FB
To 0.3mL of a solution of Hcy (3.33 × 10-4 M) in 0.05 M, pH 7.3 phosphate

buffer, is added 0.1 mL of a solution of FeCl3 (1.0 × 10-4 M) in MeOH. After the addition
of 0.6 mL of FB solution (1.67 × 10-5 M) in MeOH to the above solution containing Hcy
and FeCl3, the UV/Vis spectrum is acquired. A solution containing same amounts of Hcy
and FB except for FeCl3 is taken as the control.
4.2

Results and Discussion

•

Redox Chemistry of Biological Thiols
Biological thiols can be oxidized in nature to form thiyl radicals. The formation of

thiyl radicals in biological systems mainly includes three routes as follows:2
(i)

“Repair” reaction

This reaction often refers to the hydrogen donation process of GSH to carboncentered radicals in DNA or proteins.
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(ii)

Oxidation by reactive oxygen/nitrogen species

Some reactive oxygen/nitrogen species such as hydroxyl radical (·OH), nitrogen
dioxide radical (NO2·), and peroxyl radical (ROO·) can often react with thiols to generate
thiyl radicals.
(iii)

Enzymatic oxidation reaction

Enzymes that can catalyze the oxidation of thiols are mainly peroxidase, such as
horseradish peroxidase, lactoperoxidase, and myeloperoxidase.
The ensuing fate of these oxidizing radicals is of concern to public health. Two of
the many characteristic reactions of thiyl radicals include the formation of a reducing
disulfide radical anion (Eq. 4.1) and the formation of a reducing α-amino carbon-centered
radical (Eq. 4.2). Eq. 4.2 is an analogous process of “repairing” reactions.
RS + RS

RSSR

RS

CR

(4.1)
(4.2)

The formation of the α-amino alkyl radical of Cys was reported in 1971 by Neta.3
It was later described that the α-amino alkyl radical of GSH could be formed intramolecularly via the thiyl radical (as in Eq. 4.2).4,5 Zhao et al. reported in 1994 that
intramolecular formation of captodatively-stabilized α-amino alkyl radical in Hcy should
be particularly favorable.5a This was attributed to an intramolecular hydrogen abstraction
mechanism, which involves a favored five-membered ring transition state (Scheme 4.1).5a
Armstrong and co-workers have also made recent contributions concerning proton
abstraction of thiyl radicals. They state that during biological repair processes,
glutathione thiyl radical can undergo either an inter- or an intra-molecular process to
form a carbon-centered radical with relatively equal ability.6
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Scheme 4.1. Intra-molecular proton abstraction of thiyl radicals leading to the formation
of the α-aminoalkyl radicals
•

Selective Detection of Hcy with MV2+
The dication MV2+ was used by Zhao et al. during thorough investigations of the

equilibrium kinetics of the reducing disulfide (Eq. 4.1) and the reducing α-amino carboncentered radicals (Eq. 4.2), derived from the Hcy, Cys and GSH thiyl radicals.5 The
formation of reducing radicals was monitored via changes in the UV/Vis spectra
indicating the production of the methyl viologen radical cation (MV+·).5a Under the basic
conditions used (pH 10.5), no colorimetric selectivity between GSH, Cys and Hcy was
observed.
At neutral solution pH, thiolate anion concentration is only a fraction of that of
protonated thiol. Thus, at neutral pH, reducing disulfide radical anion formation should
be diminished (Eq. 4.1). The intra-molecular proton-coupled electron transfer process
(Eq. 4.2) which is most favored for Hcy (Scheme 4.1), should become more predominant
at physiological pH. Additionally, zwitterionic amino acids cannot captodatively stabilize
α-amino carbon-centered radicals. When the ammonium moiety is deprotonated under
alkaline conditions, rearrangement to captodatively-stabilized carbon-centered radicals
occurs much more readily and hence less selectively. We therefore reason that the
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formation of the reducing α-amino alkyl radical should occur more readily in the case of
Hcy compared to all other thiols, at neutral, rather than alkaline pH.

Figure 4.1. Selective color change in response to Hcy in solutions of MV2+. (Left to
right: no added analyte, Cys, Hcy, GSH)
Upon heating respective colorless solutions of MV2+ (4.0 mM, in pH 7.5, 0.5 M
tris buffer) containing specific biological thiols (17 mM) at reflux for 5 min, without
protection from ambient air or light, visual signaling occurs selectively for Hcy. The
solution containing Hcy can be readily seen to turn blue, from colorless. Solutions of
MV2+ containing Cys or GSH remain completely colorless upon heating (Figure 4.1).
The color formation in the Hcy-containing solution can be monitored via the appearance
of absorptions at 398 nm and 605 nm (Figure 4.2).
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Figure 4.2. UV/Vis spectrum of a MV2+ solution (4.0 mM) in the presence of Hcy (17
mM) in tris buffer (0.1 M, pH 7.5) after gentle reflux for 5 min.
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•

Selective Detection of Hcy in Human Blood Plasma with MV2+

Figure 4.3. Selective detection of Hcy in human plasma without prior deproteinization.
(added thiol left to right: none, Hcy, Cys, GSH. Inset: samples before heating.)
Common thiol determinations in plasma often require a deproteinization step after
the reduction of disulfides to release the free thiols for analysis. Under our conditions,
we find that this process may not be necessary. Upon heating in the presence of MV2+,
commercial plasma samples spiked with Hcy, Cys and GSH afford selective blue color
formation only corresponding to the presence of Hcy (Figure 4.3). This result is
completely consistent with the prior results in buffer solutions. It demonstrates that
deproteinization procedures such as centrifugation may not be necessary in this
determination technique, thereby potentially allowing for relatively facile sample
pretreatment. Work on optimizing detection limit and sensitivity is continuing.
•

Detection of Hcy with FB
In order to extend the scope and generality of selective Hcy detection, we use

electron-accepting fluorone black (Figure 4.4), a commercially available xanthene dye, to
confirm the Hcy selectivity observed in the presence of MV2+.
HO

O

HO

O
OH

Figure 4.4. The structure of FB
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Figure 4.5. UV/Vis spectra of solutions containing FB (1.0 × 10-5 M) and different
biological thiols (1.0 × 10-4 M).
Upon addition of 10 equivalent Hcy (1.0 × 10-4 M final concentration, in 0.015M,
pH 7.3 phosphate buffer) to a solution of FB (1.0 × 10-5 M final concentration, in MeOH),
an increase in absorbance at 510 nm is observed at room temperature. A similar, but
relatively smaller absorbance change is observed for Cys, GSH and penicillamine (Figure
4.5). Other amino acids (glycine, alanine, serine, methionine, glutamine, lysine, arginine,
threonine) and the disulfide homocystine do not promote a detectable absorbance change
(Figure A1).
•

Selective Detection of Hcy with FB in the Presence of PPh3
The disulfide reduction in biological samples is often accomplished with a

reducing agent such as a phosphine. We investigate the effect of PPh3 on this process,
initially in order to mimic the conditions used to prepare biological samples for analysis
via disulfide reduction. When PPh3 (45 equivalent to dye) is present, an absorbance
change only occurs in the presence of Hcy. No change is observed for Cys or other
biological thiols (Figure A2).
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Figure 4.6. Absorbance at 510 nm vs. concentrations of Cys or Hcy in the presence of
FB (1.0 x 10-5 M) and PPh3 (4.5 x 10-4 M).
Concentration-dependent dye absorbance increases are thus observed only for
Hcy. No response is observed for Cys (Figure 4.6). In addition, we observe selective
fluorescence emission increases corresponding to the presence of Hcy under these
conditions (Figure A3).
•

Investigation of the Function of PPh3
To investigate the function of PPh3 in the selective determination of Hcy, a series

of experiments have been carried out. The UV/Vis spectrum of a buffered solution of FB
with only added PPh3 exhibits absorbance increases in a similar fashion as it does when
Hcy is added. This suggests that the phosphine may act as a competing reducing agent.
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P

NMR

spectroscopy

shows

that

FB

enhances

the

formation

of

triphenylphosphine oxide (O=PPh3) in a solution of FB and PPh3 (Figure A4). After 19 h,
the formation of O=PPh3 is not observed in the PPh3 solution which doesn’t contain FB.
Whereas in the PPh3 solution which contains FB, the formation of O=PPh3 is clearly
observed. The formation of O=PPh3 is well known to proceed via the PPh3 radical cation.

41

Thus, PPh3 inhibits the reduction of FB with thiols other than Hcy by acting as a
competing reducing agent.
Hcy thus serves as the best reducing agent among the biological thiols. At least
45 equivalent PPh3 (to dye) is needed to suppress the interactions of other thiols with FB.
This is the threshold level of competing reducing agent, PPh3, which allows for only Hcygenerated spectrophotometric changes in solutions containing FB and PPh3. If a 30-fold
molar excess of Cys (to Hcy) is added to a solution of Hcy (1.0 × 10-5 M, approximating
both Hcy and Cys levels in plasma) and FB (0.5 × 10-5 M) in the presence of PPh3 (5.0 ×
10-4 M), no spectral change is observed compared to the original Hcy-FB solution (Figure
4.7).

2 equiv Hcy
Absorbance (AU)

0.3

2 equiv Hcy+ 60
equiv Cys

0.2
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0
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Figure 4.7. UV/Vis spectra of solutions containing FB (0.5 × 10-5 M), Hcy (1.0 × 10-5
M) and PPh3 (5.0 × 10-4 M) in 30 % phosphate buffer (0.015 M, pH 7.3) and 70 % MeOH
in the absence/presence of 30 equivalent Cys (to Hcy). No absorbance change is
observed due to the added excess Cys.
•

The Study of the Detection Mechanism
Solutions of fluorescein (Figure 4.8), unlike solutions of FB, do not exhibit

spectral changes in response to Hcy or other thiols. (Figure 4.9).
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Figure 4.9. Detection of Hcy (1.0 × 10-4 M) with fluorescein (1.0 × 10-5 M) in 0.015 M
phosphate buffer pH 7.3.
We thus propose that the formation of semiquinone radicals in FB is responsible
for the signal changes observed (Scheme 4.2). Electron transfer results in raising the pKa
of FB. As in the case of the addition of a base, the absorbance of the dye at 510 nm
increases. Similarly, electron transfer from Hcy carbon-centered radicals to MV2+ gives
rise to the formation of MV+·, which shows a blue color (Scheme 4.2).
•

Detection of Hcy in Human Blood Plasma with FB
We successfully use FB to determine Hcy in a commercial human blood plasma

sample via the standard addition method. A calibration curve derived from the solutions
containing added Hcy standards is shown in Figure 4.10. It exhibits linearity in the
working range from 0 to 15 μM, which is inclusive of the upper limit of healthy Hcy
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concentration. The percent recovery of Hcy is 102.9 + 7.3 %. The relative standard
deviation (RSD) is 7.1 % (n = 3).
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Scheme 4.2. Electron transfer from Hcy carbon-centered radical to MV2+ or FB.
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Figure 4.10. Calibration curve for the determination of Hcy in human plasma in the
presence of PPh3 and FB. (A is the absorbance of samples with added Hcy at 510nm; Ao
is the absorbance of samples without added standards at 510nm).
•

The Fate of the α-amino Carbon-centered Radical of Hcy
There

is

growing

interest

in

the

study

of

the

metabolites

of

hyperhomocysteinemia.7 Amino acid-derived free radicals are often implicated in DNA
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damage and the pathogenesis of disease. The readily-formed Hcy alkyl radical might be a
significant site of free radical damage initiation or propagation. We thus extend our work
in the study of byproducts formed from the Hcy carbon-centered radical under ambient
conditions. It has been reported that α-amino acid alkyl radicals form NH3 and several
other radical termination and disproportionation products under ionizing radiation and
relatively harsh oxidizing conditions.5,8 Several byproducts of Hcy alkyl radical reactions
are identified under our assay conditions by using MALDI TOF MS (Table 4.1) with/
without different matrices (Figure A5-A7).
Table 4.1. Byproducts of Hcy carbon-centered radicals

Product
NH2

KOOC

S

H2N

S

Calcd.

Found

MALDI Matrix

360.53

359.02

none

190.28

190.05
191.01

Anthracene
Dithranol

112.04

112.52

none

156.14

156.68
155.28

None
Dithranol

138.19

138.23

Dithranol

282.06

283.33

Anthracene

190.17

190.05
191.01

Anthracene
Dithranol

206.28

205.20

Anthracene

COOK

OH
KOOC

SH

H3N OH

H3N

COONa
O

NaOOC

SH
O

KOOC
NH2
COONa

S

NaOOC

NH3

NH3

HOO NH3
HS

COONa

HOO NH3
HS

COOK
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Scheme 4.3 shows a proposed mechanism of the formation of these products,
which are generated under mild conditions:

neutral pH and room temperature.

Interestingly, compounds 2 and 7 have been found in the urine of patients with
homocystinuria.9 Thus, this study may provide a starting point as a chemical model for
the reactions of the α-amino carbon-centered radical derived from Hcy in the human body
under non-radiative conditions.
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Scheme 4.3. Proposed mechanism for the formation of byproducts from Hcy α-amino
carbon-centered radical.
•

Evidence for H2S Production from Hcy Carbon-centered Radicals
In a separate experiment, the extent of formation of H2S was evaluated for

reactions of Hcy, Cys and GSH with MV2+ using hydrogen sulfide test strips. Figure
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4.11 qualitatively shows that the sample containing Hcy produces a significantly higher
amount of H2S. Should Hcy produce H2S more readily than GSH and Cys? It may have
significant implications for Hcy-based toxicity compared to GSH and Cys.

Figure 4.11. H2S test strips after contact with vapors produced by heated solutions
containing equimolar amounts of GSH (left), Cys (center) and Hcy (right) in the presence
of MV2+.
•

Effect of Transition Metals on the Detection of Hcy
The oxidation of amino acids is generally catalyzed by transition metals. The

mechanism of this process involves the formation of hydroxyl radicals (Fenton reaction).
Therefore, studies of the oxidation of amino acids can be complicated by the presence of
metal impurities in buffers and reagents. We thus investigate the effects of a chelating
agent (EDTA) and an added transition metal (Fe3+) under our conditions, for
completeness.
EDTA is a commonly used metal-chelating agent in studies of metal-catalyzed
amino acid oxidation reactions. In a study of Fenton chemistry, Stadtman et al. showed
that the oxidation of amino acids could be either stimulated or inhibited by various metal
chelating agents, depending on the actual ratios of chelating agents to iron salts.8 The
varying amino acid oxidation or inhibition of oxidation corresponding to changes in the
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ratios of chelating agents to iron salts was attributed to variations in the composition,
concentration and redox potentials of the different complexes.
Upon addition of EDTA (20 equivalent to FB) in our fluorone black assay, no
differences in the UV/Vis spectra are observed as compared to those without EDTA
(Figure 4.12).
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FB + EDTA + Cys
FB
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Figure 4.12. UV/Vis spectra of solutions containing FB (1.0 × 10-5 M) and Hcy or Cys
(1.0 × 10-4 M) in the presence/ absence of EDTA (2.0 × 10-4 M).
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Figure 4.13. UV/Vis spectra of solutions containing FB (1.0 × 10-5 M) and Hcy or Cys
(1.0 × 10-4 M) in the presence/ absence of FeCl3 (1.0 × 10-5 M).

48

In addition, no spectral changes are observed upon addition of FeCl3 (1.0 × 10-5
M) under the same conditions (Figure 4.13). The conclusion is that the mechanism
shown in Scheme 4.1 best accounts for the observed Hcy selectivity in our assays, rather
than Fenton chemistry.
4.3

Conclusion
In conclusion, the unique ability of Hcy to form reducing carbon-centered radicals

has led to the discovery of the first Hcy-selective probes, MV2+ and FB. By using these
two compounds, we have developed colorimetric methods for the selective detection of
Hcy at neutral pH. MV2+ solutions turn color selectively corresponding to the presence of
Hcy upon heating. We also selectively detect Hcy by utilizing FB and PPh3 via UV/Vis
spectroscopy at room temperature. The latter technique shows great potential for directly
determining Hcy levels in human blood plasma.
The fundamental organic chemistry of Hcy, Cys and GSH should have broader
biomedical implications. Rare metabolites such as 2, found in the urine of
homocystinurics, have been detected via the mild oxidation of Hcy at room temperature.
The identification of such byproducts derived from Hcy carbon-centered radicals may
help biomedical researchers in understanding the fate of Hcy under physiological
conditions and its biological relevance to disease.
The mechanism showed in Scheme 3.1, rather than Fenton chemistry best
accounts for the observed Hcy selectivity in our assays.
4.4

References

4.1

(a) Davis, C. J.; Lewis, P. T.; McCarroll, M. E.; Read, M. W.; Cueto, R.;
Strongin, R. M. “Simple and rapid visual sensing of saccharides”. Org. Lett. 1999,
1, 331-334. (b) Lewis, P. T.; Davis, C. J.; Cabell, L. A.; He, M.; Read, M. W.;
McCarroll, M. E.; Strongin, R. M. “Visual sensing of saccharides promoted by

49

resorcinol condensation products”. Org. Lett. 2000, 2, 589-592. (c) He, M;
Johnson, R.; Escobedo, J. O.; Beck, J. A.; Kim, K. K.; St. Luce N. N.; Davis C.
J.; Lewis, P. T.; Fronczek F. R.; Melancon, B. J.; Mrse, A. A.; Treleaven, W. D.;
Strongin, R. M. “Chromophore formation in resorcinarene solutions and the
visual detection of mono- and oligosaccharides”. J. Am. Chem. Soc. 2002, 124,
5000-5009. (d) Rusin, O.; St. Luce, N. N.; Agbaria, R. A.; Escobedo, J. O.; Jiang,
S.; Warner, I. M.; Dawan, F. B.; Lian, K.; Strongin, R. M. “Visual detection of
cysteine and homocysteine”. J. Am. Chem. Soc. 2004, 126, 438-439.
4.2

Abedinzadeh, Z. “Sulfur-centered reactive intermediates derived from the
oxidation of sulfur compounds of biological interest”. Ca. J. Physiol. Pharmacol.,
2001, 79, 166-170.

4.3

Fessenden, R. W.; Neta, P. “Electron spin resonance study of radicals produced
in irradiated aqueous solutions of thiols”. J. Phys. Chem. 1971, 75, 2277-2283.

4.4

(a) Sjöberg, L.; Eriksen, T. E.; Revesz, L. “The reaction of the hydroxyl radical
with glutathione in neutral and alkaline-aqueous solution”. Radiat. Res. 1982, 89,
255-263. (b) Grierson, L.; Hildenbrand, K.; Bothe, E. “Intramolecular
transformation reaction of the glutathione thiyl radical into a non-sulfur-centered
radical: a pulse-radiolysis and EPR study”. Int. J. Radiat. Biol. 1992, 62, 265-277.

4.5

(a) Zhao, R.; Lind, J.; Merényi, G.; Eriksen, T. E. “Kinetics of one-electron
oxidation of thiols and hydrogen abstraction by thiyl radicals from α-amino C-H
bonds”. J. Am. Chem. Soc. 1994, 116, 12010-12015. (b) Zhao, R.; Lind, J.;
Merényi, G.; Eriksen, T. E. “Significance of the intramolecular transformation of
glutathione thiyl radicals to α-aminoalkyl radicals. Thermochemical and
biological implications”. J. Chem. Soc., Perkins Trans., 1997, 2, 569-574, and
references cited therein.

4.6

For example, Rauk, A.; Armstrong, D. A.; Fairlie, D. P. “Is oxidative damage by
β-amyloid and prion peptides mediated by hydrogen atom transfer from glycine
α-carbon to methionine sulfur within β-sheets?” J. Am. Chem. Soc. 2000, 122,
9761-9767, and references cited therein.

4.7

Böger, R.H.; Bode-Böger, S. M.; Sydow, K.; Heistad, D. D.; Lentz, S. R.
“Plasma Concentration of Asymmetric Dimethylarginine, an Endogenous
Inhibitor of Nitric Oxide Synthase, is Elevated in Monkeys with
Hyperhomocyst(e)inemia or Hypercholesterolemia”. Arterioscler. Thromb Vasc.
Biol., 2000, 20, 1557-1564.

4.8

Stadtman, E. R. “Oxidation of free amino acids and amino acid residues in
proteins by radiolysis and by metal-catalyzed reactions”. Ann. Rev. Biochem.
1993, 62, 797-821.

50

4.9

Cooper, A. J. L. “Biochemistry of sulfur-containing amino acids”. Ann. Rev.
Biochem. 1983, 52, 187-222.

51

CHAPTER 5. POSTCOLUMN HPLC DETECTION OF HCY*
The determination of Hcy is often carried out in conjunction with separations.1
HPLC determination of Hcy and related thiols is currently used in large scale population
studies on the international scene. Refsum, Ueland and co-workers have made pioneering
advances in developing HPLC assays towards Hcy and related biothiol analysis, mainly
using pre-column derivatization with fluorophores.1
In pre-column HPLC detection of Hcy, a derivatizing step is often used. The
derivatizing reagents typically contain universal electrophilic alkylating groups. There
are nearly 50 thiol-reactive reagents currently sold by Molecular Probes, Inc.2 There is
thus great interest in developing agents for detecting Hcy and other biothiols.
In our laboratory, we have developed a simple HPLC post-column detection
system for the analysis of mono- and oligosaccharides based on a boronic acid-derived
chemosensor.3 Postcolumn detection allows for automation of the derivatization step and
minimizes sample processing prior to analysis. Major concerns with introducing any new
post-column techniques include (i) attaining appropriate reaction kinetics for generating
an observable signal as well as (ii) diminishing background interference.
Recently, we demonstrate the use of MV2+ and FB in an automated HPLC
postcolumn system for the determination of Hcy and other biological thiols. Both of the
compounds have shown great potentials as postcolumn detection reagents.

* Reprinted in part with permission from the Journal of the American Chemical Society,
2005, Volume 127, pages 15949-15958; Weihua Wang, Oleksandr Rusin, Xiangyang Xu,
Kyu Kwang Kim, Jorge O. Escobedo, Sayo O. Fakayode, Kristin A. Fletcher, Mark
Lowry, Corin M. Schowalter, Candace M. Lawrence, Frank R. Fronczek, Isiah M.
Warner, and Robert M. Strongin; Detection of Homocysteine and Cysteine. Copyright
2005 American Chemical Society.
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5.1

Experimental Section

•

Materials
All materials were purchased from Sigma-Aldrich and used without further

purification. HPLC grade methanol and water were obtained from EMD chemicals Inc.
Both of the postcolumn reagents were freshly prepared and degassed by helium sparging
right before use.
•

Apparatus

Pressurized helium
Sample Injection
Reagent Reservoir

Solvent Delivery

Mixing-T

Column

Reactor
Detector

Computer

Scheme 5.1. An automatic HPLC postcolumn detection system
The postcolumn detection system includes (i) a helium cylinder; (ii) a CM4000
multiple solvent delivery system (LDC/Milton Roy) (iii) a RDR-1 reagent delivery/
reaction module (Timberline), which contains a pressurized reagent reservoir, a mixing
tee, and a thermostated reaction block with a Teflon reaction coil; (iv) a Lichrospher
reverse-phase column (4.6×250 mm, 5µm; Alltech Associates Inc.); (v) a SpectroMonitor
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3100 UV/Vis detector (LDC/Milton Roy) (Scheme 5.1). The detection conditions for
each detection reagent are described below.
•

Use of MV2+ as a Postcolumn Detection Reagent
Mobile phase: TFA 0.01 M; mobile phase flow rate: 1.5 mL/min; reactor

temperature: 80 °C; detector wavelength: 610 nm.
MV2+ concentration: 0.01 M in 0.25 M carbonate buffer, pH 9.5.
•

Use of FB as a Postcolumn Detection Reagent
Mobile phase: 100 % of HPLC grade water; mobile phase flow rate: 1.5 ml/min;

reactor temperature: 80 °C; detector wavelength: 505 nm.
FB concentration: 1.25 × 10-5 M in 50/50 (v/v) mixture of MeOH and aqueous
carbonate buffer (0.25 M, pH 9.5).
5.2

Results and Discussion

•

Use of MV2+ as a Postcolumn Detection Reagent
Figure 5.1 shows a chromatogram of a mixture of Hcy and Cys (85 nmol each)

using MV2+ as a post-column detection reagent. Two well-resolved peaks are observed.
Both of the peaks are identified by comparing retention times with those of standard Hcy
and Cys.
•

Use of FB as a Postcolumn Detection Reagent
Figure 5.2a shows a chromatogram of a mixture of Hcy and Cys (28.8 nmol each)

using FB as a postcolumn chromogenic reagent. Two sharp peaks corresponding to Cys
and Hcy are observed. All other amino acids (histidine, methionine, glutamine, lysine,
glycine and serine) tested don’t exhibit any peaks (Figure 5.2b and Figure 5.3c). This, on
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one hand, excludes possible interferences from other common amino acids. On the other
hand, it is further evidences that MV2+ and FB are chemoselective probes for aminothiols.
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R e te n tio n tim e (m in )

Figure 5.1. Chromatogram of a mixture of Cys and Hcy using MV2+ as the post-column
reagent at 610nm.

Figure 5.2. Chromatograms of mixtures of: (a) Cys and Hcy, (b) histidine, methionine
and glutamine and (c) lysine, glycine and serine using FB as the postcolumn reagent.
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5.3

Conclusion
In conclusion, the above HPLC studies indicate that the kinetics of both

postcolumn reactions are fast enough for the detection of Hcy. Additionally, no
interference from other amino acids is observed. MV2+ and FB can thus serve as
prospective postcolumn reagents for the determination of Hcy and/or Cys. Currently,
optimization, calibration, application in human blood plasma and method validation are
still ongoing.
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CHAPTER 6. SYNTHESES OF LANTHANIDE COMPLEXES AS BIOSENSORS*
6.1

Introduction
My specific contribution to this collaborative work was the optimization of the

synthesis of 1 and 2. This included improvements in yield and product purity as well as
the development of an HPLC method to detect and assay 1 and 2.
The detection of neutral sugars has been of interest for over a century. A
challenge remaining in this area is to achieve sensitive and selective detection of monoand oligosaccharides at physiologically relevant pH. The molecular recognition of sugars
by lectins (carbohydrate-binding proteins other than enzymes and antibodies) in nature
has inspired work in the field.1 An important mode in this type of recognition is the
coordination of carbohydrates to a metal center, such as Ca2+, Mn2+ or other transition
metals. The carbohydrate selectivity is often achieved by a network of coordination and
hydrogen bonds.2 Many innovative metal-based detection methods have been
developed.3,4 However, since saccharides are weak ligands, elevated solution pH is
typically used to attain a useful degree of coordination and signal transduction. The need
for the detection of carbohydrate at physiological pH still persists.
Recently, metallomacrocycles have attracted great interest in the field of
supramolecular chemistry.5,6 Most of the work has focused on the design of selective

*Reprinted in part with permission from Proceedings of the National Academy of
Sciences of the United States of America, 2006, Volume 103, pages 9756-9760; Onur
Alpturk, Oleksandr Rusin, Sayo O. Fakayode, Weihua Wang, Joege O. Escobedo, Isiah
M. Warner, Williams E. Crowe, Vladimir Kral, Jeff M. Pruet, and Robert M. Strongin,
Lanthanide Complexes as Fluorescent Indicators for Neutral Sugars and Cancer
Biomarkers. Copyright 2006 National Academy of Sciences, U.S.A.
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receptors, in which metal cation(s) is/are incorporated into organic ligands. The design of
macrocyclic receptors is based on the appropriate organization of the binding sites and
the size of analytes. For instance, a class of functionalized UO2-salophene (or salen)
complexes have been developed for the detection of anionic and neutral analytes.7,8
The Shinkai group has reported a salen-Co (II) complex bearing two boronic acid groups
for sugar sensing wherein Co (II) provides a well-defined distance between two boronic
acid groups.9
La3+ and Ca2+ have been shown to exhibit relatively stronger affinity for sugars
compared to most other metal ions.10,11

The similar properties of lanthanides allow

trivalent lanthanide ions to be employed as useful substitutes for Ca2+ in biomedical
research. In addition, lanthanides can extend their ligand coordination number via
“ligand-sphere” extension, leading to highly coordinated complexes.12
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Figure 6.1. Salophene-lanthanide complexes 1 and 2.
Hence, we propose that La3+-salophene complex 1 (Figure 6.1) may be useful for
the determination of saccharides at neutral pH. La3+, which has good sugar affinity,
would be a binding site. Glycolic side chains would help to achieve water solubility.
The determination of anionic sugars, such as sialic acid, at neutral pH is also a
challenge of great current interest. An increase or decrease in total sialic acid levels (free
circulating and glycoconjugated) in biological fluids or tissues can indicate the
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occurrence of certain cancers. A variety of methods, including colorimetric methods,
fluorometric methods, GLC and HPLC methods have been developed.13-18 In these
procedures, a hydrolysis step is typically required to release bound sialic acid residues
from the glycoconjugates. The acid-catalyzed liberation of sialic acid often results in the
destruction of analytes.14, 19-21 In the case of enzymatic hydrolysis, incomplete release of
sialic acid residues has been observed.22

New effective sensing agents for the

determination of sialic acid are thus needed.
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Figure 6.2. Left: Coordination of GM1 to Eu3+. Right: Structure of free sialic acid
Sillerud et al. have reported favorable cooperative interactions of the
oligosaccharide and sialic acid moieties of gangliosides with Eu3+. As compared with
sialic acid, the higher affinity of Eu3+ to GM1 was attributed to: i) an electrostatic
interaction of Eu3+ with GM1 sialic acid carboxylate group; ii) secondary interactions
with the proximal hydroxyls of the oligosaccharide (Figure 6.2).23
Additionally, the smaller the ionic radius of a lanthanide, the larger are the
intramolecular interactions among its ligands. Since Eu3+ has a smaller ionic radius
compared to La3+, we hypothesized that compound 2 (Figure 6.1) may function as a good
sensing agent for anionic gangliosides under neutral conditions.
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6.2

Results and Discussion
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Scheme 6.1. Syntheses of Compounds 1 and 2. 1, Ln=LaCl3, 2, Ln=EuCl3.

Figure 6.3. 1H-NMR spectrum of 4 in DMSO-d6.
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1,2

The synthesis of 1 and 2 starts with the alkylation of catechol with o-acetyl-2-(2chloro-ethoxy)-ethanol in the presence of K2CO3 to give the diacetates 3 (Scheme 6.1).
The diacetates are chosen because the unprotected diol would lead to some byproducts
under the acidic conditions of the following nitration step. Aromatic nitration of 3 gives
the dinitro compound 4 in high yield. The 250 MHz 1H NMR spectrum of 4 is well
resolved and clearly shows the symmetrical nature of the molecule. The presence of a
two proton singlet at ca. δ 7.79 indicates the formation of the dinitrated product (Figure
6.3). Deacetylation in methanolic potassium hydroxide in the following step affords 5.
Catalytic hydrogenation of 5 gives rise to 6, which is used immediately for the synthesis
of 1 or 2 to prevent any unwanted oxidation.
•

HPLC Purity Screening of Compounds 1 and 2
To verify the purity of 1 and 2, high performance liquid chromatography is used.

At the detection wavelength of 360 nm, only one peak is observed at 3.96 min for 1, 4.02
min for 2, respectively (Figure 6.4, 6.5). This indicates that both compounds are pure
enough to be used in the following analytical detection processes.

Figure 6.4. Chromatogram of a solution of 1 in MeOH.
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Figure 6.5. Chromatogram of a solution of 2 in MeOH.

•

Detection of Neutral Sugars at Physiological pH with Compound 1
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Figure 6.6. Relative fluorescence emission (400 nm) changes observed in solutions of
1(5.53 × 10-6 M) in the presence of mono-, oligosaccharides, anions (1.1 × 10-3 M), BSA
(1 mg/mL) and a mixture of BSA and glucose (1 mg/mL and 1.1 × 10-3 M, respectively)
in HEPES buffer solution (pH 7.0). The standard deviation (n=3 for each analyte) of the
relative fluorescence intensity ranges from 0.01-0.027.
Addition of saccharides (1.1 × 10-3 M) to a solution of 1 (5.53 × 10-6 M, 0.1 M
HEPES buffer, pH 7.0) gives rise to fluorescence emission increases (Figure 6.6).
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Common anions (citrate, phosphate and pyrophosphate), which exist in biological fluids
promote relatively weaker emission responses under these conditions (Figure 6.6). In
addition, bovine serum albumin-containing solutions exhibit emission increases only
when glucose is present.
•

Detection of Gangliosides at Neutral Condition with Compound 2
Compared with free sialic acid and non-sialic acid-containing ganglioside asialo

GM1 (Figure 6.7), sialic acid-containing ganglioside GM1 is selectively detected by
compound 2 (Figure 6.8). Free sialic acid binding to metals has been reported by Saladini
et al..24 The carboxylate, pyranose ring and oxygens of glycerol side-chain are all
involved in the coordination. Sialic acid-containing GM1 binds to Eu3+ via multiple
coordination sites. Besides the sialic acid moiety, proximal oligosaccharide hydroxyls
also play important roles in the coordination (Figure 6.2).
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Figure 6.7. The structures of asialo-GM1 and GM1.
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Figure 6.8. Fluorescence intensity change of solutions of 2 (5.53 × 10-6 M) in response to
added gangliosides (0.5 mg/mL, ca. 10-4 M each) and sialic acid (1.0 × 10-3 M) in 0.1 M
HEPES buffer solution (pH 7.0). Excitation 360 nm, emission 400 nm.
6.3

Conclusion
Two salophene-lanthanide complexes, 1 and 2, have been synthesized and

characterized. The design of compound 1 is inspired by calcium-dependent recognition of
saccharides by C-type lectins. It can be used in the detection of neutral sugars at
physiological pH. Compound 2 has shown potential for the selective detection of sialic
acid-containing gangliosides under neutral conditions. Electrostatic interactions of Eu3+
with the carboxylate group of the sialic acid moiety as well as the secondary interactions
of Eu3+ with proximal oligosaccharide hydroxyls plays important roles in the signal
transduction.
6.4
•

Experimental Section
General Methods
All chemicals were purchased from Sigma-Aldrich or Cambridge Isotope Labs

and used without further purification. Gangliosides were purchased from Calbiochem.
Fluorescence spectra were recorded on a spectrofluorimeter SPEX Fluorolog-3 equipped
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with double excitation and emission monochromators and a 400W Xe lamp. MS were
acquired on a Bruker ProFLEX III MALDI-TOF mass spectrometer. 1H and

13

C NMR

spectra were acquired on a Bruker DPX-250 or DPX-300 spectrometer. All δ values were
reported in ppm. FT-IR spectra were recorded on a Bruker Tensor 27 IR
spectrophotometer.
HPLC purity screening was performed on a CM4000 multiple solvent delivery
system connected to a LiChrospher 100 RP-18 (5 µm) endcapped column (250 × 4.6 mm)
and a SpectroMonitor 3100 UV/Vis detector (LDC/Milton Roy). The mobile phase is
30/70 (v/v) water/MeOH, the flow rate 1.0 mL/min and the detector wavelength was set
to 360 nm.
•

Synthesis of 1,2-bis(2-(2(2-acetoxy(ethoxyethoxy))))benzene 3.25 To 90 mL of

DMF under N2, 3.76 g of K2CO3 (27.24 mmol), 1.0 g of catechol (9.80 mmol) and 2.1 g
of O-acetyl-2-(2-chloro-ethoxy)-ethanol (18.16 mmol) are added. The final mixture is
heated overnight at 100 ˚C. The reaction is monitored by thin layer chromatography
(EtOAc / Hexane 1:3). Upon completion, the reaction mixture is cooled to room
temperature. K2CO3 is filtered. The filtrate is diluted with EtOAc (60 mL) and washed
with H2O (30 mL × 4). The organic phase is dried over Na2SO4 and concentrated under
reduced pressure. The product is purified by column chromatography and obtained as a
yellow oil (1.5 g, 44.5%). 1H NMR (250 MHz, DMSO-d6) δ (ppm): 1.99 (6H, s, CH3)
3.69 (8H, m, CH2) 4.09 (8H, m, CH2) 6.92 (4H, m, ArH). 13C NMR (62.5 MHz, DMSOd6) δ (ppm): 21.6, 64.0, 69.1, 69.3, 69.8, 115.2, 122.1, 149.2, 171.2.
•

Synthesis of compound 4. 25 1.6 g of 3 (4.32 mmol) is dissolved in 50 mL of DCM.

The solution is cooled on an ice bath. To the solution, 12 mL fuming HNO3 is added. The
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solution is stirred overnight at room temperature. The reaction mixture is poured onto a
mixture of ice and water (80 mL). The organic phase is collected, neutralized with 10%
NaHCO3 and washed with H2O. The organic layer is dried over anhydrous Na2SO4. The
solvent is removed under reduced pressure. The product is chromatographed on silica gel
to give compound 4 (1.6 g, 80.5%). 1H NMR (250MHz, DMSO-d6) δ (ppm): 1.97 (6H, s,
CH3) 3.68 (2H, t, CH2) 3.80 (2H, t, CH2) 4.10 (2H, t, CH2) 4.33 (2H, t, CH2) 7.79 (2H, s,
ArH).

13

C NMR (62.5 MHz, DMSO-d6) δ (ppm): 21.4, 55.7, 64.0, 69.3, 70.4, 110.1,

136.7, 152.0, 171.2.
•

Synthesis of compound 5. The deprotection of 4 is carried out with 2 equiv KOH in

a MeOH. 0.52 g compound 4 (1.13 mmol) is dissolved in 30 mL MeOH. 0.13 g KOH
(2.26 mmol) is added. The mixture is stirred at room temperature for 4 hours. The
reaction mixture is neutralized with 2N HCl. MeOH is removed under reduced pressure.
The product is extracted with DCM. After washing with H2O, the organic layer is dried
over anhydrous Na2SO4. After removing DCM under reduced pressure, compound 5 is
obtained (0.33 g, 76.9%). Compound 5 is used without further purification.
•

Synthesis of compound 1. Compound 5 (0.2 g, 0.53 mmol) is dissolved in MeOH

(15 mL). Raney Ni is added to the solution. Hydrogenation is carried out at 50 psi and
monitored via hydrogen consumption. The reaction mixture is filtered through celite. The
filtrate solution containing 6 is immediately used in the next step to prevent any
unwanted oxidation. To a refluxing solution of LaCl3 (0.13 g, 0.53 mmol) in 10 mL
MeOH, O-vanillin (0.16 g, 1.1 mmol) in 10 mL MeOH and the solution containing 6 are
simultaneously added over 20 min. The solution is heated at reflux for 2 h. The reaction
mixture is concentrated under reduced pressure and washed with EtOAc (5 mL × 3). The
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product is obtained as a dark-red solid (0.37 g).

13

C NMR (62.5 MHz, DMSO-d6) δ

(ppm): 49.4, 56.5, 56.9, 61.1, 69.7, 69.8, 73.1, 73.3, 113.8, 114.0, 118.4, 120.0, 120.9,
123.4, 149.2, 151.4, 192.8. MALDI-TOF (m/z): calcd. C30H34LaN2O10, 721.13; obsd,
721.48. IR 3206.20, 1614.33, 1439.22, 1209.10, 1036.87.
•

Synthesis of 2. Compound 2 is synthesized according to the procedure described

above for 1 except EuCl3 is used instead of LaCl3. The product is obtained as a dark-red
solid (0.35 g).

13

C NMR (62.5 MHz, DMSO-d6) δ (ppm): 49.4, 56.6, 57.0, 61.1, 69.7,

69.8, 73.1, 73.4, 118.4, 119.3, 120.1, 120.9, 123.4, 147.3, 149.0, 149.3, 151.6, 192.8.
MALDI-TOF (m/z): calcd. C30H34EuN2O10, 735.14; obsd, 735.34. IR 3104.00, 1638.44,
1444.54, 1214.76, 1018.07.
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APPENDIX A. COLORIMETRIC DETECTION OF HCY
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Figure A1. UV-Vis spectra of FB (1.0 x 10-5 M) in 30 % phosphate buffer (0.015 M, pH
7.3), 70 % MeOH in the presence of various amino acids (1.0 x 10-4 M). No absorbance
changes are observed due to the presence of the amino acids.
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Figure A2. UV-Vis spectra of FB (1.0 x 10-5 M) in 30 % phosphate buffer (0.015 M, pH
7.3) and 70 % MeOH in the presence of various biothiols (1.0 x 10-4 M) and PPh3 (4.5 x
10-4 M).
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Figure A3. Fluorescence emission spectrum of FB (1.0 × 10-6 M) in the presence of
PPh3 (4.5 × 10-5 M) and Hcy or Cys (1.0 × 10-5 M). This demonstrates selective
fluorescence emission responses to the presence of Hcy.
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Figure A4. 31P-NMR spectra of PPh3 in CD3OD:D2O 7:3 in the absence of FB (bottom)
and in the presence of FB (middle) after 19 hours. The resonance at 8.80 ppm
corresponds to PPh3. The resonance at 31.25 ppm corresponds to O=PPh3 (top). It
shows that the formation of O=PPh3 is promoted in the presence of FB.
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Figure A5. MALDI-TOF of the reaction mixture of FB and Hcy (no matrix)
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Figure A6. MALDI-TOF of the reaction mixture of FB and Hcy (anthracene matrix)
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Figure A7. MALDI-TOF of the reaction mixture of FB and Hcy (dithranol matrix)
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APPENDIX B. SYNTHESIS OF LANTHANIDE COMPLEXES

Figure B1. 13C-NMR spectrum of 1 in DMSO-d6.
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Figure B2. FTIR spectrum of 1.
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Figure B3. MALDI TOF MS spectrum of 1.
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Figure B4. 13C-NMR spectrum of 2 in DMSO-d6.
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Figure B5. FTIR spectrum of 2.
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Figure B6. MALDI TOF MS spectrum of 2.
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Figure B7. 1H-NMR spectrum of 3 in DMSO-d6.
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Figure B8. 13C-NMR spectrum of 3 in DMSO-d6.
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Figure B9. 1H-NMR spectrum of 4 in DMSO-d6.
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Figure B10. 13C-NMR spectrum of 4 in DMSO-d6.
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Figure B11. 1H-NMR spectrum of 5 in DMSO-d6.
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